As of February 21, the Corona 19 virus has reached over 200 people, and it has been announced that a Korean-American treatment developer has completed the development of the Corona vaccine and will soon begin animal testing. According to the Chosun Ilbo on February 21, it has already developed a DNA vaccine to prevent new coronavirus infections in Wuhan, China, and plans to conduct clinical trials in the United States as early as June after an imminent animal test.
Corona vaccine developer turned out to be Inobio, a U.S. bio company, and Joseph Kim, a Korean-American.
Joseph Kim is a world-renowned scientist who has already developed Ebola vaccine, MERS vaccine, Zika virus vaccine, and MERS vaccine before developing the Corona virus vaccine.
He is a world-renowned scientist who shares opinions with Bill Gates, the head of Microsoft in the United States, whenever a new epidemic breaks out in the world.
Corona vaccine developer Joseph Kim says the Chinese government is giving permission as soon as possible, and the South Korean government is in talks as well.
The last Zika virus vaccine in Brazil took about seven months from the initial stage to human trials.
The development of the Corona 19 virus could be shortened by a month or two.
The viruses that cause MERS and coronavirus 19 are all bacteria that belong to the coronavirus. Joseph Kim's company Inobio developed the MERS vaccine with about 67 billion won from the Korea Federation for Infectious Diseases. Although many other companies have developed vaccines, Inobio is the only company that has gone to clinical trials. According to CEO Kim, once the Corona 19 virus is developed, we will implement the same method of vaccinating MERS twice a month, just as we used the previous vaccine.
Corona vaccine developer Joseph Kim went to the U.S. at 11 p.m., graduated from MIT, studied immunology at the University of Pennsylvania, and received a master's degree in business administration at Wharton School. I worked as a research team for a pharmaceutical company and founded a venture company, VGX, with Professor Weiner, a professor of guidance. Next, we implemented injection technology for DNA development, M&A with Inobio and stock listing in 2014. Joseph Kim said new viruses like the Corona 19 virus are virtually impossible for companies and countries to cope with, and that international organizations need to take the lead in supporting vaccine research and development and storing vaccines through public goods.
댓글